Company news

Solid Biosciences Inc. news in 2025

Solid Biosciences Inc.'s news releases, calls and decks from 2025, newest first.

View company

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

December 16, 2025

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

December 8, 2025

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

December 1, 2025

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

November 17, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences

November 11, 2025

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

November 6, 2025

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

November 3, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences

October 30, 2025

Solid Biosciences to Present at Upcoming Scientific Meetings

October 1, 2025

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

September 25, 2025

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

September 23, 2025

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12, 2025

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 23, 2025

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 8, 2025

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference

April 30, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

April 29, 2025

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 12, 2025

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 6, 2025

Solid Biosciences Announces Pricing of Underwritten Offering

February 18, 2025

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

February 18, 2025

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

January 20, 2025

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

January 14, 2025

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

January 6, 2025

Decks in 2025